Perspective Therapeutics (NYSE:CATX) Earns Outperform Rating from Wedbush

Perspective Therapeutics (NYSE:CATX)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a research report issued to clients and investors on Monday,RTT News reports. They currently have a $11.00 price objective on the stock. Wedbush’s price target points to a potential upside of 348.98% from the company’s previous close.

Several other equities research analysts have also recently commented on the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $16.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Oppenheimer decreased their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, November 22nd. HC Wainwright started coverage on Perspective Therapeutics in a research note on Thursday, March 13th. They set a “buy” rating and a $10.00 target price for the company. Scotiabank started coverage on Perspective Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $15.00 target price for the company. Finally, Brookline Capital Management raised Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $14.56.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at $2.45 on Monday. The stock has a 50-day moving average of $3.10 and a 200-day moving average of $7.02. Perspective Therapeutics has a 1-year low of $2.32 and a 1-year high of $19.05.

Institutional Investors Weigh In On Perspective Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. FMR LLC grew its stake in Perspective Therapeutics by 3,994.9% in the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after acquiring an additional 5,370,392 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Perspective Therapeutics by 8.0% in the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after purchasing an additional 355,685 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its holdings in shares of Perspective Therapeutics by 4.3% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company’s stock valued at $9,375,000 after purchasing an additional 120,991 shares in the last quarter. Octagon Capital Advisors LP lifted its holdings in shares of Perspective Therapeutics by 62.1% in the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock valued at $7,352,000 after purchasing an additional 882,528 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after purchasing an additional 1,192,812 shares in the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.